Hyaluronic Acid
Sodium Hyaluronate · Hyaluronan · The Water-Binding Polymer
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The oral supplement, as distinct from injectable fillers and intra-articular knee injections, sits at preliminary-to-modest. For skin hydration the best evidence is a set of short (8 to 12 week) double-blind placebo-controlled RCTs plus a 2025 meta-analysis of seven trials reporting improved hydration, elasticity and wrinkle depth, but sample sizes are small, follow-up is brief, and several trials carry ties to the ingredient supplier (for example the Gao 2023 skin trial included three authors affiliated with Bloomage Biotech, which supplied the HA). For knee osteoarthritis a 2016 review by Oe and colleagues covered thirteen double-blind placebo-controlled RCTs (2008 to 2015, doses 48 to 240 mg/day) reporting reduced pain and effusion, yet the field is dominated by manufacturer-linked studies and the mechanism for an orally taken polymer remains partly inferred. Signal is consistent and low-risk, but not yet independent or long enough to grade above preliminary. I set ev to 2 (down from the current 3), separating the modest oral signal from the much stronger injectable and topical literature that the marketing halo borrows from.
- FDA
- Legal supplement; FDA medical devices (intra-articular injection)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Low risk for healthy adults, mild GI upset the main complaint; coordinate with oncology during active cancer treatment and with a clinician in pregnancy, since those contexts are understudied for the oral form.
Hyaluronic acid is the water-binding glycosaminoglycan that fills nearly every interstitial space in the body, from joint synovial fluid and skin dermis to the vitreous of the eye. Karl Meyer and John Palmer isolated it from bovine vitreous at Columbia University in 1934. It is long established in medicine as an injectable, both as a dermal filler and as an intra-articular gel for knee osteoarthritis, and those uses have their own substantial evidence. The oral supplement is a much newer and more modest story that took off in the 2000s once biofermentation made HA cheap. Small short trials suggest oral HA can nudge skin hydration and ease knee discomfort, but the studies are brief, often supplier-linked, and separate from the injectable data that the marketing tends to lean on.
The water-binding polymer that fills nearly every interstitial space, and a recent oral category with modest evidence.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Hyaluronic acid is a high-molecular-weight glycosaminoglycan polymer composed of repeating disaccharide units (D-glucuronic acid and N-acetyl-D-glucosamine). The body produces it continuously in nearly every tissue, synovial fluid in joints, dermis in skin, the vitreous humor of the eye, the umbilical cord, and the extracellular matrix throughout the body. Its signature property is water binding: a single HA molecule can hold up to 1000x its weight in water, producing the gel-like consistency that lubricates joints and hydrates skin. The body produces about 5g of HA daily in an adult, with about a third turning over each day, implying continuous synthesis and degradation in healthy tissue. The oral supplement mechanism is genuinely puzzling. HA is a large polymer (typically 100,000 to several million Daltons in tissue) that should not survive digestive proteolysis intact. Modern formulations use lower-molecular-weight HA (often 50,000-200,000 Da) that fragments further in the gut to oligosaccharides absorbed in the colon. These fragments don't directly replace tissue HA but appear to signal endogenous HA synthesis through TLR4 receptor pathways and potentially through gut microbiome interactions. The mechanism is more "signaling and stimulation" than "structural replacement", similar to the modern understanding of collagen peptides. The injection mechanism (intra-articular HA for knee osteoarthritis) is mechanistically different and substantially better evidenced: direct viscoelastic supplementation of synovial fluid plus local anti-inflammatory effects.
How it is taken
Oral HA dosing for joint and skin endpoints converges on 80-200mg/day of branded oral formulations (Mobilee, Hyabest) for 8-12 weeks minimum. Take with or without food, bioavailability appears comparable. Effects accumulate slowly; expect a quarter before evaluating clinical change for joint endpoints, 8-12 weeks for skin endpoints. Vitamin C co-supplementation supports endogenous HA synthesis (ascorbate is cofactor for proline hydroxylation in connective tissue synthesis). Higher doses (300mg+) don't produce proportionally greater effects in published trials. Intra-articular injection is a completely different mechanism and dose regimen, orthopedic specialist guidance, typically 1-5 injections per course over 3-5 weeks. Cosmetic dermal fillers are performed by dermatology/plastic surgery and represent a third distinct use category.
- Oral joint
- 200mg/day Mobilee or equivalent for 12+ months
- Oral skin
- 80-200mg/day for 8-12 weeks minimum
- Injectable (joint)
- 1-5 injection course; specialist-administered
- Time to effect (oral)
- 8-12 weeks skin; 3-6 months joint
- Food state
- With or without food
- Higher doses
- Limited evidence above 200mg/day
- Vitamin C cofactor
- 100-200mg supports synthesis (mechanistic)
- Trial commitment
- 3-12 months for meaningful clinical change
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Oral Sodium Hyaluronate (Mobilee®, Hyabest®)
Branded oral HA formulations with molecular weight optimized for oral bioavailability. Mobilee® (Bioiberica) and Hyabest® (Kewpie) are the most-clinically-studied oral forms. Lower MW (50,000-200,000 Da) than tissue HA. Used in essentially all positive oral HA trials.
Standard Oral Hyaluronic Acid
Generic oral HA without molecular weight specification. Quality varies; some products use very high MW HA that may not fragment effectively in the gut. Reasonable choice with reputable third-party-tested brands but verify MW disclosure.
Intra-Articular HA Injection (Hyaluronic Acid Viscosupplementation)
Direct injection into joint by orthopedic specialist. Products include Synvisc, Hyalgan, Supartz, Euflexxa, Monovisc. Substantially stronger evidence than oral for knee osteoarthritis specifically. Single course typically 1-5 injections over 3-5 weeks; effects last 3-6 months. Insurance coverage varies.
Cosmetic Dermal Fillers (Restylane, Juvéderm)
Cross-linked HA for dermatological filling of wrinkles and tissue volume restoration. Effects typically last 6-18 months depending on product. The clearest documented HA dermal evidence; the mass-market injectable category. Distinct from oral or topical.
Topical HA Serums
Cosmetic skincare products with HA at varying molecular weights. Higher MW provides surface hydration without penetration; lower MW (often "fragmented" HA) penetrates more deeply. Most leave-on facial serums use combinations. Modest but real hydration evidence over hours.
HA Eye Drops (Artificial Tears with HA)
Common in dry eye management. HA-containing artificial tears (Refresh Optive, Systane Hydration, others) provide longer-lasting lubrication than non-HA formulas. Real symptomatic benefit in dry eye syndrome.
HA + Collagen Peptide Combinations
Common consumer joint/skin formulations combining oral HA with branded collagen peptides (Verisol, BioCell). BioCell specifically combines undenatured type-II collagen with chondroitin and HA. Some additive evidence; difficult to attribute effects to individual components.
High-Dose HA (300mg+)
Some products market 300-500mg/day. Limited evidence that higher doses produce proportionally better effects. Most positive trials used 80-200mg/day. Pay-more-for-less category.
Who it works for, and who it does not
Knee osteoarthritis (orthopedic injection)
Intra-articular HA viscosupplementation has the strongest HA evidence, Cochrane meta-analyses support modest pain and function improvement lasting 3-6 months. Mainstream orthopedic option; insurance coverage variable. Effects smaller than corticosteroid injection acutely but longer-lasting.
Knee osteoarthritis (oral supplementation)
Japanese oral HA trials (Yoshida 2009, Tashiro 2012, Oe 2016) consistently show modest symptomatic benefit at 200mg/day over 12 months. Effects smaller and slower than injection. Reasonable adjunct in mild-moderate OA.
Dry skin / skin hydration
Multiple oral HA trials and Kim 2014 meta-analysis support modest skin hydration and elasticity improvements over 8-12 weeks at 80-240mg/day. Effect sizes smaller than topical or injectable HA but real.
Cosmetic dermatology (injectable)
Dermal filler HA injections (Restylane, Juvéderm) have the strongest evidence of any HA form for cosmetic outcomes. Effects last 6-18 months. Performed by trained dermatologists/plastic surgeons. Different category from oral or topical HA.
Dry eye syndrome
HA-containing artificial tears provide longer-lasting lubrication than non-HA formulas. Real symptomatic benefit. Mainstream ophthalmology option; OTC and Rx forms available.
Other joint OA (hip, shoulder, ankle)
Most evidence is in knee OA. Limited trial data for other joints; some off-label injection use in shoulder and hip. Generally less established than knee protocols.
Tendinopathy and ligament injury
Preliminary evidence for HA injection in tendinopathy (Achilles, rotator cuff). Limited trial data; not standard orthopedic practice. Oral evidence very thin.
Wound healing
HA dressings and gels have established evidence for chronic wound healing (diabetic ulcers, surgical wounds). Mechanism: maintains moist wound environment plus signaling effects. Clinical wound care; different category from oral.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Collagen Peptides
Mechanistically complementary, both extracellular matrix components with overlapping connective tissue evidence. BioCell formulations specifically combine HA with undenatured type-II collagen. Common combination in joint protocols.
Vitamin C
Vitamin C is cofactor for proline hydroxylation in collagen synthesis and supports endogenous HA synthesis. Mechanistically defensible co-supplementation. 100-200mg vitamin C reasonable pairing.
Chondroitin Sulfate
Both glycosaminoglycans with overlapping joint matrix evidence. Common combination in joint formulations.
Glucosamine
Common joint protocol pairing. Different mechanisms (HA: water-binding, signaling; glucosamine: substrate, anti-inflammatory) with theoretically complementary effects.
MSM
Sulfur donor for connective tissue. Common in triple-stack joint formulations (HA + glucosamine + chondroitin + MSM). Modest additive evidence.
Astaxanthin
Antioxidant with independent joint and skin evidence. Sometimes combined with HA in skin-focused formulations.
Anticoagulants
No documented anticoagulant interaction at supplement doses. Intra-articular injection may have different considerations.
Active cancer (with tumor expressing CD44)
Some preliminary concern about HA and tumor growth in cancers expressing CD44 receptor. Coordinate with oncology during active treatment; mechanism speculative for oral doses.
What to look for on the label
Look for: branded oral formulations with molecular weight disclosure (Mobilee, Hyabest); third-party testing (NSF, USP); explicit MW range (50,000-200,000 Da typical for bioavailability); fermentation-derived source for purity; clinical trial citation on labels of premium products. Avoid: products without MW disclosure; very high MW HA in oral form (unlikely to be bioavailable); proprietary blends obscuring HA content; products without third-party verification; gummies with high sugar and unclear HA dose.
Safety in detail
- Oral HA: very well tolerated at studied doses (80-300mg/day). No documented serious adverse events in clinical trials.
- Mild GI upset is the most common side effect at higher doses; resolved by dividing dose or reducing.
- Intra-articular injection: usual injection-related risks (infection, bleeding) plus rare immune reactions. Performed under sterile orthopedic conditions.
- Dermal filler injections: bruising, swelling, occasional vascular complications (rare but serious). Trained provider essential.
- Cancer concerns: HA is produced endogenously throughout life, supplementation does not create tumors. Some preliminary concern about HA and growth of specific cancers expressing CD44; oncology coordination during active treatment is prudent.
- Pregnancy and breastfeeding: limited systematic safety data at supplement doses. Endogenous production continues normally during pregnancy. OB-GYN guidance for supplementation.
- Pediatric: oral HA generally not appropriate for routine pediatric use without specific indication.
- Drug interactions: minimal at oral supplement doses. No documented major interactions.
- Source considerations: most modern HA is fermentation-derived (Streptococcus zooepidemicus or other bacteria). Older animal-sourced (cockscomb extract) less common in modern products.
What people get wrong
Often saidOral hyaluronic acid is just expensive water.
ActuallyWhile the mechanism is mechanistically unusual (large polymer that shouldn't survive digestion), multiple Japanese trials at 80-200mg/day show modest but reproducible skin and joint endpoints. Effects are smaller than topical or injectable but real.
Often saidAll hyaluronic acid products work the same.
ActuallyForm factor matters enormously. Intra-articular injection, dermal filler, oral supplement, topical serum, and eye drops are five distinct categories with different mechanisms, evidence bases, and use cases.
Often saidHigher dose oral HA produces better effects.
ActuallyPublished trials cluster at 80-200mg/day; products marketing 300-500mg/day have limited evidence of proportional benefit. Pay-more-for-less category.
Often saidHyaluronic acid causes cancer.
ActuallyHA is produced endogenously throughout life. Supplementation does not create tumors. Some preliminary concern about HA in specific cancers expressing CD44 receptor; oncology coordination during active cancer treatment is prudent. The "causes cancer" framing is misleading.
Often saidHyaluronic acid injection cures osteoarthritis.
ActuallyIntra-articular injection provides modest symptomatic benefit lasting 3-6 months per course. It is symptomatic management, not cure. The aesthetic medicine marketing of "cure" or "permanent solution" overstates the orthopedic evidence.
Often saidTopical HA serums penetrate to deep skin layers.
ActuallyHigh MW HA in topical serums provides surface hydration without meaningful deeper penetration. Low MW or fragmented HA penetrates somewhat better. Most cosmetic claims about "regenerating from within" are marketing.
Often saidAnimal-source HA is more natural and better.
ActuallyRooster cockscomb extract was the original source but is largely supplanted by bacterial fermentation, which is cleaner, more consistent, and avoids animal-source allergens. "Natural" framing has not aged well as fermentation quality has improved.
Who profits, and who pushes back
Mainstream rheumatology (oral HA)
Oral hyaluronic acid for osteoarthritis has not been incorporated into major orthopedic or rheumatology guidelines as routine therapy. The Japanese trial inheritance is genuine but smaller than the intra-articular injection evidence base. Most US orthopedic practice reserves HA for injectable use under specialist administration.
Cochrane intra-articular HA reviews
Multiple Cochrane reviews have characterized intra-articular HA injection as producing modest pain and function improvement at 4-26 weeks post-injection, meaningful but heterogeneous across studies. The injection has real benefit but should not be oversold as a cure for osteoarthritis.
Aesthetic medicine critics
Dermal HA fillers are real and effective for soft tissue augmentation, but the aesthetic medicine marketing has substantially outpaced realistic patient expectations. Effects last 6-18 months, not permanently. Complications including vascular occlusion are rare but serious. Trained provider selection matters more than product brand.
Endre Balazs
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Founded the modern pharmaceutical HA industry. Developed Healon ophthalmic viscoelastic. Independent academic with substantial commercial outcomes. Died 2015; legacy continues through HA-derivative products.
Bioiberica (Mobilee®)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Major commercial backer of oral HA clinical research, particularly Spanish and European trials. Disclosed industry source for much of the branded oral HA evidence base.
Kewpie (Hyabest®)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Built the Japanese oral HA functional food category through 1990s-2000s. Substantial trial program disclosed. The dominant Japanese consumer brand.
Allergan / AbbVie (Juvéderm)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Dominant dermal filler manufacturer. Aggressive direct-to-consumer marketing through aesthetic medicine channels. Disclosed commercial interest in HA category.
Cosmetic dermatology profession
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Significant commercial interest in injectable HA category. Trade societies and conferences promote the category extensively. Procedural revenue substantial.
Dr. Howard Sobel
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
High-visibility cosmetic dermatology voice on HA fillers. Substantial commercial practice in aesthetic medicine. Industry consultation disclosed.
How we got here
Karl Meyer and John Palmer isolated hyaluronic acid at Columbia University in 1934 from bovine vitreous humor. The name combines "hyaloid" (Greek for glassy, describing the vitreous) and "uronic acid", reflecting both the biological origin and the molecular structure. Meyer's laboratory continued characterization through the 1940s-50s, identifying HA in synovial fluid, dermis, and other tissues. Modern pharmaceutical use began with Endre Balazs, a Hungarian-American researcher who developed pharmaceutical-grade HA at MIT and Columbia in the 1960s-70s. Balazs founded Biotrics in 1968 and developed Healon, the ophthalmic surgery viscoelastic that revolutionized cataract surgery. The intra-articular injection use case followed in the 1980s with Synvisc (Genzyme), Hyalgan (Fidia), and other products. Dermal filler use traces to bovine collagen products in the 1980s, but HA fillers (Restylane launched by Q-Med in 1996) substantially supplanted collagen by the early 2000s, with longer-lasting and lower-immunogenicity profiles. The HA dermal filler market has grown to billions of dollars globally with Allergan (Juvéderm, acquired by AbbVie 2020) and Galderma (Restylane) dominating. Oral HA emerged as a Japanese functional food category in the 1990s-2000s with Kewpie's Hyabest leading the supplement market. Western expansion of oral HA accelerated in the 2010s as a skin-and-joint wellness category. Bioiberica's Mobilee® launched in Europe as a branded oral HA with clinical trial backing. The fermentation revolution in the 2000s, bacterial production replacing rooster cockscomb extract, substantially reduced costs, improved purity, and enabled the modern supplement and cosmetic categories. Bloomage Biotechnology (China) became the world's largest HA manufacturer through fermentation scale-up.
- 1934Karl Meyer isolates HA at Columbia from bovine vitreous humor
- 1960s-70sEndre Balazs develops pharmaceutical-grade HA at MIT/Columbia
- 1968Biotrics founded; pharmaceutical HA category begins
- Late 1970sHealon (ophthalmic viscoelastic) revolutionizes cataract surgery
- 1980sSynvisc and Hyalgan intra-articular injection products launch
- 1996Restylane HA dermal filler launches in Europe
- 1990s-2000sJapanese oral HA category emerges (Hyabest by Kewpie)
- 2000sFermentation production scales; costs drop substantially
- 2002Sato oral HA dermal hydration trial, first major oral evidence
- 2009Yoshida oral HA knee OA trial, joint application
- 2014Kim meta-analysis confirms modest oral HA dermal effects
- 2020AbbVie acquires Allergan ($63B), including Juvéderm filler portfolio
What we do not know
- How oral HA fragmentation in the gut produces tissue effects when intact molecules should not survive digestion, the mechanism remains incompletely characterized.
- Whether the Japanese trial inheritance translates to non-Japanese populations, most positive oral HA trials are Japanese cohorts.
- How oral HA compares head-to-head with intra-articular injection over comparable time scales for knee OA, direct comparison trials are limited.
- Whether different molecular weight HA produces different tissue targeting (joint versus skin) when taken orally.
- Whether the modest preliminary signal in tendinopathy will resolve into clinical injection protocols.
- Whether the HA + collagen peptide combination produces meaningfully better outcomes than either alone, head-to-head trials limited.
Legal status
Universally available as a dietary supplement (oral form), cosmetic ingredient (topical), medical device (intra-articular injection for orthopedic use), and prescription cosmetic (dermal fillers). Major manufacturers include Bioiberica (Mobilee), Kewpie (Hyabest), Genzyme (Synvisc), Allergan/AbbVie (Juvéderm), Galderma (Restylane). The pharmaceutical-grade injection market dominates revenue; the oral supplement category is growing rapidly through 2020s consumer wellness trends. No regulatory restrictions on oral supplements in any major market.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Modern HA production is dominated by bacterial fermentation (Streptococcus zooepidemicus), Bioiberica (Spain), Kewpie (Japan), and several Chinese manufacturers (Bloomage Biotechnology) dominate the global supply. Pharmaceutical-grade and dermal filler HA goes through extensive purification and cross-linking; supplement-grade is less processed. Animal-sourced HA (rooster cockscomb extract) is the traditional source and persists in some niche products. Modern fermentation-derived material is generally cleaner, more consistent, and avoids animal-source allergens.
At a glance
- Structure
- Glycosaminoglycan polymer (glucuronic acid + N-acetyl-glucosamine)
- Body production
- ~5g daily synthesis in adult
- Water binding
- Up to 1000x own weight
- Oral standard dose
- 80-200mg/day
- Time to effect (oral)
- 8-12 weeks skin; 3-6 months joint
- Intra-articular dose
- 1-5 injection course
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hyaluronic Acid. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Oral HA (300 kDa, 100 to 200 mg/day) improved skin hydration at 2 to 8 weeks in a 129-woman double-blind placebo-controlled trial; three authors affiliated with the HA supplier Bloomage
2016 review of 13 double-blind placebo-controlled oral HA knee osteoarthritis RCTs, doses 48 to 240 mg/day, reduced pain and effusion, no adverse events, proposed TLR-4/IL-10 and gut-bacteria oligosaccharide mechanism
2025 meta-analysis of seven oral HA RCTs finds significant improvement in skin hydration, elasticity and wrinkle depth
2025 randomized double-blind placebo-controlled trial in 150 healthy adults reports oral sodium hyaluronate improved skin hydration, barrier function and signs of aging
12-month double-blind placebo-controlled trial: 200 mg/day oral HA eased knee osteoarthritis symptoms; capsules made by an ingredient manufacturer
Karl Meyer and John Palmer isolated hyaluronic acid from bovine vitreous in 1934 at Columbia University and named it from hyalos plus uronic acid
Journal of Biological Chemistry, The Discovery of Hyaluronan by Karl Meyer
HA extraction historically from rooster comb; modern microbial biofermentation replaced animal sourcing; Bloomage began fermentation-based mass production around 2000
Hyaluronic Acid Extraction Methods, Sources and Applications (PMC)
Bloomage established 2000, first to mass-produce HA by microbial fermentation in China, first Jinan plant online 2005
Sodium hyaluronate subject to FDA GRAS notification for food use; FDA noted molecular-weight and drug-like-effect concerns and DSHEA exclusionary-clause complications for the oral form
Dual role of HA in cancer: high-molecular-weight HA associated with homeostasis and protection, low-molecular-weight fragments associated with pro-tumor signaling in tumor tissue
Hyaluronic Acid as a tumor progression agent, review (MDPI IJMS)
Molecular weight governs absorption: high-MW HA taken up by intestinal epithelial cells, low-MW absorbed in cecum and distributed via blood; MW over ~1e5 rarely absorbed intact in cell models
Oral sodium hyaluronate skin trial, Scientific Reports (PMC)
The studies that matter
Karl Meyer isolation1934
Columbia University isolation from bovine vitreous humor. Meyer named the substance from hyaloid (Greek for "glassy") plus uronic acid. Foundational structural biochemistry of glycosaminoglycans.
Endre Balazs ophthalmological development1960s-70s
Hungarian-American researcher developed pharmaceutical-grade HA (Healon) for ophthalmic surgery viscoelastic. Foundational clinical use and the basis of the modern HA pharmaceutical industry.
Bayer intra-articular HA trials1990s
Multiple trials of intra-articular HA injection (Synvisc, Hyalgan, Supartz) for knee osteoarthritis: modest symptomatic benefit with effect lasting 3-6 months per injection course. Established the orthopedic clinical use.
Sato oral HA dermal hydration trial2002
Japanese trial of oral HA in women with dry skin: 240mg/day for 8 weeks improved skin moisture and elasticity markers. Among the first oral HA dermal trials.
Yoshida oral HA knee osteoarthritis trial2009
Japanese trial of 200mg/day oral HA for 12 months in knee osteoarthritis: meaningful symptom improvement versus placebo. Established the oral HA joint use case with longer time scales than injection.
Kim oral HA skin elasticity meta-analysis2014
Pooled analysis of oral HA dermal trials: consistent modest improvements in skin hydration and elasticity over 8-12 weeks at 80-240mg/day. Effect sizes smaller than topical or injectable but real.
Tashiro oral HA knee OA trial2012
Followup Japanese trial confirming 200mg/day oral HA for 12 months produces meaningful knee OA symptom improvement. Replication of Yoshida findings.
Oe oral HA quality of life trial2016
Japanese trial in knee OA with synovial fluid HA measurement: oral supplementation increased synovial HA concentrations modestly, suggesting bioavailability mechanism beyond simple oral degradation.
Cochrane intra-articular HA review2006-2015
Multiple Cochrane updates on intra-articular HA: modest pain and function improvement at 4-26 weeks post-injection. Effect size meaningful but heterogeneous across studies.